More recently the combination of the PD-L1 antibody atezolizumab and the VEGF inhibitor bevacizumab demonstrated significant improvement in overall survival (OS) compared to sorafenib, changing the treatment landscape of patients with advanced HCC [7], leading to an unprecedented median OS of 19.2 months [8,9]. The gene discussed is CD274; the disease is hepatocellular carcinoma.